Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: ARID1A
Name: AT-rich interaction domain 1A
Location: 01p36.11
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT05396833 Study of Tuvusertib M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor DDRiver Solid Tumors 320 View
NCT02893085 Pancreatico-biliary Tumor Mutation Profiling in Bile Samples View
NCT05523440 Bevacizumab andor Niraparib in Patients With Recurrent Endometrial andor Ovarian Cancer With ARID1A Mutation View
NCT04953104 Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression View
NCT05154994 Tremelimumab DurvalumabMEDI4736 Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma View
NCT03297424 A Study of PLX2853 in Advanced Malignancies View
NCT04872036 Prognostic Biomarkers in Patients With Urothelial Carcinoma View
NCT05023655 Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation View
NCT04065269 ATr Inhibitor in Combination With OlaparibDurvalumab MEDI4736 in Gynaecological Cancers With ARId1A Loss or no Loss View
NCT05690035 Tislelizumab Combined With Fruquintinib for Metastatic pMMRMSS Colorectal Cancer View
NCT04284202 PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC View
NCT04315155 Evaluating Safety Efficacy Belinostat Combo w Nivo Alone w Ipi in Patients w Treated MetastaticAdvanced Carcinomas w ARID1A Lof Mutation View
NCT04493619 PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer View
NCT05950464 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer View
NCT04716686 Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma View
NCT04957615 Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression View
NCT05226507 A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer View
NCT06617923 Study of Senaparib in Combination With Temozolomide View
NCT06518564 Avelumab and M1774 in ARID1A-mutated Endometrial Cancer Prior IO View